ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.

IPO Year:

Exchange: NASDAQ

Website: abeonatherapeutics.com

Peers

$CERE

$TSHA

Recent Analyst Ratings for Abeona Therapeutics Inc.

Date	Price Target	Rating	Analyst
6/2/2025	$19.00	Outperform	Oppenheimer
3/5/2025	$16.00	Outperform	Oppenheimer
7/3/2024	$15.00	Buy	H.C. Wainwright
5/30/2024	$21.00	Buy	Stifel
11/30/2021	$5.00 → $1.00	Outperform → Market Perform	SVB Leerink
11/29/2021	$5.00 → $4.00	Buy	HC Wainwright & Co.
7/19/2021	$8.00 → $5.00	Buy	HC Wainwright & Co.

See more ratings

Abeona Therapeutics Inc.

Peers

Recent Analyst Ratings for Abeona Therapeutics Inc.

Abeona Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Vazzano Joseph Walter was granted 13,333 shares, increasing direct ownership by 3% to 504,579 units (SEC Form 4)

Chief Financial Officer Vazzano Joseph Walter sold $120,294 worth of shares (17,795 units at $6.76), decreasing direct ownership by 3% to 491,246 units (SEC Form 4)

Chief Executive Officer Seshadri Vishwas sold $342,570 worth of shares (50,676 units at $6.76), decreasing direct ownership by 4% to 1,303,761 units (SEC Form 4)

SVP, General Counsel O'Malley Brendan M. sold $70,777 worth of shares (10,470 units at $6.76), decreasing direct ownership by 3% to 378,245 units (SEC Form 4)

Chief Executive Officer Seshadri Vishwas covered exercise/tax liability with 885 shares, decreasing direct ownership by 0.07% to 1,354,437 units (SEC Form 4)

Director Alvino Mark sold $12,760 worth of shares (2,000 units at $6.38), decreasing direct ownership by 2% to 90,435 units (SEC Form 4)

Director Alvino Mark sold $45,440 worth of shares (8,000 units at $5.68), decreasing direct ownership by 8% to 92,435 units (SEC Form 4)

Chief Executive Officer Seshadri Vishwas sold $119,500 worth of shares (25,000 units at $4.78), decreasing direct ownership by 2% to 1,355,322 units (SEC Form 4)

Chief Financial Officer Vazzano Joseph Walter covered exercise/tax liability with 685 shares, decreasing direct ownership by 0.13% to 509,041 units (SEC Form 4)

SVP, General Counsel O'Malley Brendan M. covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.05% to 388,715 units (SEC Form 4)